2020 dividend forecasts: BP, Vodafone and Astrazeneca

Paul Summers takes a look at what income investors might expect from three FTSE 100 (INDEXFTSE:UKX) favourites next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Earlier this month, my Foolish colleague Edward Sheldon looked at the dividend credentials of FTSE 100 financial giants Lloyds and Barclays, as well as revived supermarket Tesco going into 2020. Today, I’m doing the same with three other stocks, all of which are popular with those investing for income.

As Edward quite rightly stated back then, please remember that the numbers stated below are subject to change, particularly as we could see quite a bit of movement in the market before and after the election

BP

FY2020 dividend forecast: 41.2 cents (32p)
FY2020 prospective yield: 6.41%

Oil behemoth BP (LSE: BP) hasn’t had the best time of late, giving away the gains it had made in the first few months of 2019 over the second half of the year due to a falling oil price. That said, a lower valuation means the dividend yield now stands at 6.41% — more than the FTSE 100 average and slightly higher than Royal Dutch Shell. This payout is likely to be covered by earnings almost 1.4 times. That’s a little lower than I would normally like, but certainly better than it once was.

As always, a lot depends on things BP can’t control. Assuming 2020 brings the black gold bulls back from the shadows, however, now might be as good a time as any to invest.  

Vodafone

FY2021 dividend forecast: 9.4 cents (8.1p)
FY2021 prospective yield: 5.17%

There was a time when I would avoid shares in Vodafone (LSE: VOD) like the plague thanks to its dogged refusal to reduce its unaffordable dividend. Now that this has finally happened, I’m prepared to be a little more welcoming. Considering that its share price has climbed 19% since the announcement back in May, it seems I’m not alone. 

That’s not to say that I think income investors should necessarily pile into the stock. Vodafone’s proposed 9.4 cents per share cash return in FY2021 (beginning 1 April 2020) will still only be covered just 1.1 times by expected profits. Moreover, the company still carries an extraordinary amount of debt on its balance sheet — the reduction of which will depend on its ability to offload its European mobile mast business and continue taking contracts from rivals (the recent capture of Virgin Media from BT is an example). 

2019 could go down as the year that Vodafone’s fortunes began to turn, but I’d still proceed with caution. 

Astrazeneca

FY2020 dividend forecast: 275 cents (214p)
FY2020 prospective yield: 2.89%

Pharmaceutical powerhouse Astrazeneca (LSE: AZN) has been one of the index’s standout performers in 2019 with the share price a little over 25% higher today than where it was at the start of the year.

In contrast to the situation at BP, this has resulted in Astra’s yield moving lower. The firm is expected to return around 214p per share in FY2020 which equates to a yield of just 2.89%. Positively, dividend cover has improved over recent years and next year’s cash payout should be covered around 1.56 times by profits.

My only real concern with Astrazeneca right now is that the stock looks expensive relative to the general market and to peer GlaxoSmithKline (at 27 vs 14 times forecast earnings). Should sterling rise on December 13 following a perceived breakthrough on Brexit, it’s possible the former’s share price could come off the boil (since Astra makes most of its money overseas). As such, anyone considering the stock may wish to put off their purchase for now.

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Female student sitting at the steps and using laptop
Investing Articles

UK stocks: the contrarian choice for 2026

UK stocks aren’t the consensus choice for investors at the moment. But some smart money managers who are looking to…

Read more »

Investing Articles

Down 20% in 2025, shares in this under-the-radar UK defence tech firm could be set for a strong 2026

Cohort shares are down 20% this year, but NATO spending increases could offer UK investors a huge potential opportunity going…

Read more »

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

New to investing? Here’s Warren Buffett’s strategy for starting from scratch

Warren Buffett says he could find opportunities to earn a 50% annual return in the stock market if he was…

Read more »

Investing Articles

Can the sensational Barclays share price do it all over again in 2026?

Harvey Jones is blown away by what the Barclays share price has been doing lately. Now he looks at whether…

Read more »

Investing Articles

Prediction: in 2026 mega-cheap Diageo shares could turn £10,000 into…

Diageo shares have been burning wealth lately but Harvey Jones says long-suffering investors in the FTSE 100 stock may get…

Read more »

Investing Articles

This overlooked FTSE 100 share massively outperformed Tesla over 5 years!

Tesla has been a great long-term investment, but this lesser-known FTSE 100 company would have been an even better one.

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

I’m backing these 3 value stocks to the hilt – will they rocket in 2026?

Harvey Jones has bought these three FTSE 100 value stocks on three occasions lately, averaging down every time they fall.…

Read more »

Investing Articles

Can the barnstorming Tesco share price do it all over again in 2026?

Harvey Jones is blown away by just how well the Tesco share price has done lately, and asks whether the…

Read more »